Serum Amyloid A in Stable Patients with Chronic Obstructive Pulmonary Disease Does Not Reflect the Clinical Course of the Disease

• Published in: International journal of molecular sciences Vol. 24; no. 3; p. 2478
• Main Authors: Maskey-Warzęchowska, Marta, Rubinsztajn, Renata, Przybyłowski, Tadeusz, Karwat, Krzysztof, Nejman-Gryz, Patrycja, Paplińska-Goryca, Magdalena, Chazan, Ryszarda
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 27.01.2023; MDPI
• Subjects: Airway management; Amyloid; Biomarkers; Blood; Chronic obstructive pulmonary disease; Cluster analysis; Clustering; clusters; Disease Progression; Eosinophils; Humans; Inflammation; Interleukin 6; Interleukin 8; Leukocytes (eosinophilic); Lung - chemistry; Lung diseases; Neutrophils; Obstructive lung disease; Patients; Peripheral blood; Proteins; Pulmonary arteries; Pulmonary Disease, Chronic Obstructive; Pulmonary functions; Respiratory function; Serum Amyloid A Protein - analysis; stable COPD; Tumor Necrosis Factor-alpha; amyloid; stable COPD; inflammation; clusters
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms24032478

Serum amyloid A (SAA) is a good systemic marker of the exacerbations of chronic obstructive pulmonary disease (COPD), but the significance of SAA in stable patients with COPD has not been widely investigated. We aimed to evaluate the SAA level in peripheral blood from stable patients with COPD and to search for correlations between SAA and other inflammatory markers and clinical characteristics of the disease. Serum SAA, IL-6, IL-8, TNF-alpha, basic blood investigations, pulmonary function testing and a 6-min walk test were performed. The correlations between SAA and other inflammatory markers, functional performance and the number of disease exacerbations were evaluated. A total of 100 consecutive patients with COPD were analyzed. No correlations between SAA and inflammatory markers as well as pulmonary function were found. Hierarchical clustering identified two clusters incorporating SAA: one comprised SAA, PaO and FEV and the second was formed of SAA and nine other disease markers. The SAA level was higher in patients with blood eosinophils < 2% when compared to those with blood eosinophils ≥ 2% (41.8 (19.5-69.7) ng/mL vs. 18.9 (1.0-54.5) ng/mL, respectively, = 0.04). We conclude that, in combination with other important disease features, SAA may be useful for patient evaluation in stable COPD.